Navigation Links
Amarin Reports Top-Line Results of two Phase III Studies of,Miraxion in Huntington's Disease

counter use; Amarin's ability to protect its patents and other intellectual property; claims and concerns that may arise regarding the safety or efficacy of Amarin's product candidates; governmental laws and regulations affecting Amarin's operations, including those affecting taxation; Amarin's ability to maintain sufficient cash and other liquid resources to meet its operating requirements; general changes in UK and US generally accepted accounting principles; growth in costs and expenses; and the impact of acquisitions, divestitures and other unusual items, including Amarin's ability to integrate its acquisition of Amarin Neuroscience Limited. A further list and description of these risks, uncertainties and other matters can be found in Amarin's Annual Report on Form 20-F for the fiscal year ended December 31, 2006 and in its Reports of Foreign Issuer on Form 6-K furnished to the SEC.

CONTACT: Contacts: Amarin +44-(0)-207-907-2442, Rick Stewart, ChiefExecutive Officer, Alan Cooke, Chief Financial Officer,; Investors: Lippert/Heilshorn &Associates, Inc. +1-212-838-3777, Anne Marie Fields; Media: Powerscourt+44-(0)-207-250-1446, Rory Godson Victoria Brough investor.relations@amarincorp.com

Ticker Symbol: (NASDAQ-NMS:AMRN)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:12/16/2009)... TechniScan, Inc. (OTC Bulletin Board: TSNI) ... engaged in the development and commercialization of an ... Joe Pepper, PhD, has been appointed to the ... Ken Hungerford commented, "Joe has extensive experience running ... OEC Medical and U-Systems, both of whom compete ...
(Date:12/16/2009)... Inc., a new clinical stage company developing innovative ... on its novel GFPA NMDA receptor modulators, today ... meeting showed that its lead compound GLYX-13 demonstrated ... of the CNS-related side effects seen with other ... also showed that GLYX-13,s antidepressant effects were evident ...
(Date:12/16/2009)... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) is ... Morgan Healthcare Conference at the Westin St. Francis ... 2010. Michael N. Chang, Optimer,s President and Chief ... Time (5:30 p.m. Eastern Time). ,, (Logo: ... this presentation will be accessible on the Investors ...
Breaking Medicine Technology:In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 3Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 5Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 6Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference 2DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America 59892 1DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America 59892 2DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America 59892 3Bioidentical Hormones a True Prevention for Breast Cancer 59889 1Bioidentical Hormones a True Prevention for Breast Cancer 59889 2Gamida Cell and Cellerix Partner on Feasibility Study 14558 1Gamida Cell and Cellerix Partner on Feasibility Study 14558 2Gamida Cell and Cellerix Partner on Feasibility Study 14558 3
... Lexicon,Pharmaceuticals, Inc. (Nasdaq: LXRX ) announced ... clinical trial with LX6171, an oral drug candidate,for ... such as,Alzheimer,s disease, schizophrenia, and vascular dementia. The ... of a new oral-suspension,formulation in healthy elderly subjects ...
... Neurobiological,Technologies, Inc. (Nasdaq: NTII ) (NTI(R)) today ... interim results,for XERECEPT(R) at the Annual Meeting for ... and Chief Executive Officer of NTI, stated, "We,are ... of XERECEPT,and the prospects for this drug, which ...
Other Medicine Technology:Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders 2Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders 3Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders 4Celtic Pharma Provides Update on XERECEPT(R) Clinical Program 2Celtic Pharma Provides Update on XERECEPT(R) Clinical Program 3Celtic Pharma Provides Update on XERECEPT(R) Clinical Program 4
(Date:12/16/2009)... survey of Fortune 1000 employers strongly indicates that wellness programs ... benefits. , ... Minneapolis, MN (PRWEB) ... companies reveals that 78 percent of employers have improved employee ... program. In the survey, conducted by Hallmark Insights, ...
(Date:12/16/2009)... Dec. 16 Tyco International Ltd. (NYSE: ... of Michael E. Daniels for election to the ... General Meeting on March 10, 2010. ,, ... Global Technology Services group of International Business Machines ... for IBM,s Global Services business operations consisting of ...
(Date:12/16/2009)... 16 Dale Buchanan, owner of Supreme Ultimate ... a weight loss contest for his students in the new ... are not competing for their own prize or against each ... the Tri County Humane Society in Boca Raton, ... loses between January 4 and February 28, 2010 I will ...
(Date:12/16/2009)... Study finds 6- to 11-month interval lessens complication risks , , ... bundle of joy has had such a profound impact on ... take a breath. A new study suggests that you ... pregnant again, and that more than 11 months could be ... interval between pregnancies was less than six months, the chances ...
(Date:12/16/2009)... received a further 1.6 million Euro in capital funding to ... in order to meet the rapidly growing demand for this promising ... A/S that continue to own each about 50% of the company. ... ... Unisense FertiliTech A/S has received a further 1.6 million Euro ...
Breaking Medicine News(10 mins):Health News:Hallmark Insights' Employer Survey Reveals Cost-Savings Benefits of Health & Wellness Programs 2Health News:Tyco International Files Preliminary Proxy Proposing Election of New Director 2Health News:Fitness Trainer Motivates Clients with Weight Loss to Help Raise Money for Animal Shelter 2Health News:For Babies' Sake, Pregnancy Spacing Matters 2Health News:For Babies' Sake, Pregnancy Spacing Matters 3Health News:Increased Capital Funding for Unisense FertiliTech A/S Will Help Meet Demand for New Assisted Reproduction Device 2
... that millions of newborn babies, //children and mothers die each ... of better healthcare by governments and donor countries. ... the health situation in several countries has not improved in ... ,According to the WHO African countries accounted for 19 of ...
... Canadian cities reveals that the legal prescription drugs such ... heroin, raising questions about drug control in the country. ... or prescription painkillers are at increasing rate though heroin ... Canada for years. ,Dr. Benedikt Fischer, a ...
... its readiness to increase its health sector cooperation with ... products. ,"We hope to enhance cooperation in the ... and doctors' exchange programmes," Hamad bin Abdullah Al-Manie, the ... ,Al-Manie, who is currently in India, was speaking at ...
... are holiday traditions, but UT Southwestern Medical Center experts warn ... for the 6 million Americans who have diabetes and don’t ... obesity, can be a silent killer because its symptoms aren’t ... disease or other maladies. ,That’s bad news for ...
... A New survey reveals that majority of doctors' fail in ... problems. //Four in five GPs are not able to correctly ... can pose a risk to long-term health. ,The ... taskforce Act Against Allergy and is sponsored by SHS International. ...
... practitioners need better resources and support to care for ... researchers. // ,In an editorial for ... general practice and family health specialists have outlined new ... in which partner violence is occurring. ...
Other Medicine News:Health News:WHO Attributes Death of Millions in Africa to Treatable diseases 2Health News:Prescription Opioids Abused More Than Heroin - A Report Says 2Health News:Holiday Gluttony Can Spell Disaster for Undiagnosed Diabetics 2Health News:Majority Of Doctors Tend To Ignore Milk Allergy Cases In Babies 2Health News:Tackling Violence in Families 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: